We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.11 | 4.91% | 2.35 | 2.30 | 2.40 | 2.30 | 2.20 | 2.20 | 1,317,704 | 16:35:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.81M | -0.0114 | -2.02 | 7.67M |
From Apr 2019 to Apr 2024
TIDMIMM
RNS Number : 4832E
Immupharma PLC
09 February 2018
9 February 2018
ImmuPharma PLC
("ImmuPharma" or the "Company")
Holding in Company
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, announces that on 8 February 2018 it received notification that Alto Invest no longer holds a notifiable interest in the Company.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
For further information, please contact:
ImmuPharma plc (www.immupharma.com) +44 (0) 207 152 Tim McCarthy, Chairman 4080 Lisa Baderoon, Head of Investor Relations +44 (0) 7721 413 lisa.baderoon@immupharma.com 496 -------------------------------------- ------------------ Northland Capital Partners Limited David Hignell, Jamie Sportswood (Corporate Finance) +44 (0) 203 861 Rob Rees (Corporate Broking) 6625 -------------------------------------- ------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLXKLFBVLFZBBK
(END) Dow Jones Newswires
February 09, 2018 09:00 ET (14:00 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
